Pre-made Gedivumab benchmark antibody ( Whole mAb, anti-Influenza A HA therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Gedivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
39.29 (gedivumab) is fully human neutralizing monoclonal antibody against influenza A. 39.29 is a neutralizing monoclonal antibody that recognizes the hemagglutinin (HA) glycoprotein of all 16 subtypes and neutralized both group 1 and group 2 influenza A viruses.
| Products Name (INN Index) | Pre-Made Gedivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody |
|---|---|
| INN Name | Gedivumab |
| Target | Influenza A HA |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 4kvn:HL |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Genentech |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Influenza A virus infections |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | Influenza A HA |
| Package |
